La vendita allo scoperto per Cadrenal Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cadrenal Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Report sulle vendite allo scoperto

Cadrenal Therapeutics

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics Inc

Biotech

General

LTRN

Lantern Pharma & Starlight Therapeutics Announce Presentation Of LP-184  Phase 1b Trial Design And Preclinical Data In Glioblastoma At Society for Neuro-Oncology 2024

Canaccord Genuity analyst Brian McNamara maintains Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) with a Buy and lowers the price target from $48 to $45.

News

Price Target

Analyst Ratings

CENT

Canaccord Genuity Maintains Buy on Central Garden & Pet, Lowers Price Target to $45

Canaccord Genuity analyst Kingsley Crane maintains Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) with a Buy and lowers the price target from $28 to $25.

ALAR

Canaccord Genuity Maintains Buy on Alarum Technologies, Lowers Price Target to $25

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and raises the price target from $67 to $71.

Barclays Maintains Overweight on Xcel Energy, Raises Price Target to $71

Critical Metals Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) ("Critical Metals Corp" or "the Company"), a leading mining development company focused on critical metals and minerals and producing strategic products essential to electrification and next generation technologies for Europe and its western world partners, today provided a project update for the Tanbreez Greenland Rare Earth Mine (the "Tanbreez Project"), one of the world's largest rare earth assets located in Southern Greenland. In connection to the drilling, the Company has discovered one of the world's highest concentrations of Gallium, an essential rare earth element for the production of computer chips and defense applications.
Based on initial results obtained from Critical Metals Corp's recent drilling program, four high-grade zones have now been identified on the site. These zones are expected to play a significant role in the Company's strategy for optimizing its mining operations and increasing throughput (the Tanbreez Project is currently licensed for 500,000 metric tons per year). The identification of these zones is a key milestone in the ongoing development of the project.

CRML

Critical Metals Corp Discovers 147 PPM Of Gallium At Its Tanbreez Project; Says "4 High-Grade Zones Have Now Been Identified On The Site, Zones Are Expected To Play A Significant Role In The Co's Strategy For Optimizing Its Mining Operations And Increasing Throughput"

Barclays analyst Jared Shaw maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Overweight and raises the price target from $24 to $26.

Barclays Maintains Overweight on Old National, Raises Price Target to $26

The Q3 earnings report for Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) was released on Tuesday, November 26, 2024 at 08:30 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Icecure Medical missed estimated earnings by 0.0%, reporting an EPS of $-0.08 versus an estimate of $-0.08.
Revenue was up $335 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.01 in the previous quarter, leading to a 1.0% drop share price change the next day.
Here's a look at Icecure Medical's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.08</td>
<td>-0.07</td>
<td>-0.09</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>930K</td>
<td>880K</td>
<td>1.17M</td>
<td>1.17M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.01M</td>
<td>743K</td>
<td>1.25M</td>
<td>327K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Icecure Medical <a href="https://www.benzinga.com/quote/ICCM/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ICCM

Icecure Medical Earnings Review: Q3 Summary

<a href="https://www.globenewswire.com/Tracker?data=SRbbH_fWlobCg0PXl43R4xu6d8j-iiHze5ibnZvXOE-EUFeq0DTq1-ZiYMfddeEknmQ9vK-IILuugPVrukJjUQ==">Gelteq Limited</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) ("Gelteq" or the "Company"), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss.
Gelteq Co-Founder and CEO Nathan Givoni stated, "Our recent IPO was undertaken to provide the necessary capital and awareness of our technology to commence larger scale sales, whilst balancing our research and development activities. To see such volumes entering production so soon after the IPO is a testament to our team executing our plans, together with market validation on our gel-based technology. This production run demonstrates our ability to sell our products to end-users across the world and our ability to begin deriving revenues in the near term."
Gelteq Co-Founder and Executive Chairman Simon Szewach stated, "Earlier this year, we strengthened our partnership with Monash Innovation Labs, which allows us to effectively scale and meet our client needs, while ensuring the quality of products. The orders connected to this production run are substantial and we believe that they represent the start of even larger volume orders to come."

Global

GELS

Gelteq Announces That In November, 400,000 Units Of Its Gel Solution Are Entering Into Production; Units Will Fulfill Orders Made For Clients In The U.S And Australia; Delivery Is Expected In January 2025 For Sales Across The Two Countries As Well As In The UAE And In Asia

TPET

Trio Petroleum Secures Option Extension To Acquire Remaining 17.75% Working Interest Of Asphalt Ridge To Feb. 10, 2025

Betting activity on Polymarket suggests significant skepticism about President-elect Donald Trump's promise to impose a <a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">25% tariff on goods</a> from Mexico and Canada.
What Happened: As of now, market <a href="https://polymarket.com/event/will-trump-impose-25-tariff-on-mexicocanada?tid=1732619786757">odds</a> give the tariff's implementation only a 30% chance by the proposed Jan. 31, 2025 deadline, despite Trump's strong rhetoric on the issue.
Trump on Monday announced his intention to implement the tariff as part of his first executive orders after taking office. 
In a <a href="https://truthsocial.com/@realDonaldTrump/posts/113546215051155542">statement</a> on Truth Social, Trump said, "On January 20th, I will sign all necessary documents to charge Mexico and Canada a 25% Tariff on ALL products coming into the United States." He justified the measure as a response to the &#8220;invasion&#8221; of illegal immigrants and drugs, including fentanyl, coming across the U.S. borders with Mexico and Canada.
He added, "This tariff will remain in effect until such time as Drugs, in particular Fentanyl, and all Illegal Aliens stop this Invasion of our Country!"
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42172993/bitcoin-slides-below-95000-analyst-predicts-potential-correction-to-85000">Bitcoin Slides Below $95,000 — Analyst Predicts Potential Correction To $85,000</a>
Why It Matters: Polymarket bettors remain skeptical about the feasibility of Trump's tariff plan.
While the statement has stirred political and economic debate, only 30% of bettors currently believe that the tariff will be implemented by the specified date. 
The remaining 70% seem to view the promise as unlikely to materialize within the stated timeframe, citing potential political hurdles, economic implications and international pushback.
If enacted, the tariff could significantly impact trade relations between the United States and its neighboring countries. Canada and Mexico are two of the U.S.'s largest trading partners, with billions of dollars in goods crossing the borders daily. 
<a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">Economists have warned</a> that such tariffs could disrupt supply chains and increase costs for American consumers.
Inflation may bump permanently back over 3% if a universal tariff is enacted, <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">according to Goldman Sachs</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42171439/solana-meme-coin-platform-pump-fun-faces-backlash-over-scandalous-livestreams-but-polymarket-traders-arent-convinced-theyll-go-dark">Solana Meme Coin Platform Pump.Fun Faces Backlash Over Scandalous Livestreams, But Polymarket Traders Aren&#8217;t Convinced It&#8217;ll Go Dark</a></li>
</ul>
Image: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trump Threatens 25% Tariffs On Canada, Mexico Until 'Invasion' Is Stopped, But Polymarket Traders Aren't Convinced

Truist Securities analyst Michael Ciarmoli reiterates Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $187 to $226.

Reiteration

Truist Securities Reiterates Buy on Woodward, Raises Price Target to $226

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $105 to $109.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $109

FEMY

Femasys Announces Peer-Reviewed Publication Of FemaSeed Data In The Journal of Gynecology & Reproductive Medicine

Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.66 by 1.52 percent. This is a 19.28 percent decrease over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $200.16 million which beat the analyst consensus estimate of $164.00 million by 22.05 percent. This is a 7.23 percent increase over sales of $186.66 million the same period last year.

Tsakos Energy Navigation Q3 EPS $0.67 Beats $0.66 Estimate, Sales $200.16M Beat $164.00M Estimate

Barclays analyst Adrienne Yih maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Underweight and raises the price target from $28 to $34.

BBWI

Barclays Maintains Underweight on Bath & Body Works, Raises Price Target to $34

Truist Securities analyst Patrick Scholes maintains Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) with a Buy and raises the price target from $60 to $61.

Truist Securities Maintains Buy on Travel+Leisure, Raises Price Target to $61

Milestone Scientific Inc. (NYSE:<a href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced its approval on contract for the Federal Supply Schedule (FSS), also known as the GSA Schedule, for the CompuFlo&#xAE; Epidural System. This significant milestone follows the Company's earlier registration with the U.S. Government's System for Award Management (SAM) in March 2023.
The FSS designation positions Milestone Scientific as a pre-vetted contractor with pre-negotiated pricing for its CompuFlo&#xAE; Epidural System and related consumable products. FSS contracts are initially awarded to sell products and services to the government for a five-year base period and can be extended through three additional five-year option periods, allowing for a potential total contract duration of up to 20 years. This streamlined procurement process allows federal agencies to save time and money while securing Milestone Scientific's innovative technologies.
The CompuFlo&#xAE; Epidural System utilizes Milestone Scientific's patented Dynamic Pressure Sensing Technology&#xAE;, offering real-time feedback to ensure accurate needle placement during epidural procedures. This innovation enhances patient safety and comfort, reducing the risk of complications associated with traditional techniques.
The inclusion of Milestone Scientific on the FSS opens significant opportunities within federal healthcare systems, including the Department of Defense (DoD), the Department of Veterans Affairs (VA), and the Indian Health Service (IHS):
<ul>
<li>Veterans Health Administration (VHA): The VHA is the largest integrated healthcare system in the United States, providing care at 1,380 facilities, including 170 VA Medical Centers and 1,193 outpatient sites. About one-third of the 9.1 million veterans enrolled in the VHA experience chronic pain, a higher prevalence than in the general population. &nbsp;</li>
<li>Department of Defense (DoD): The Military Health System (MHS) serves approximately 9.5 million beneficiaries, including active-duty service members, retirees, and their families, through 45 hospitals, 572 clinics, and 115 dental clinics. According to a RAND study, between 31% and 44% of active-duty U.S. service members experience chronic pain, highlighting a significant burden within the DoD population. Chronic pain is considered a leading cause of disability and reduced readiness among service members, making effective pain management solutions a critical need for the DoD. 
<ul>
<li>Indian Health Service (IHS): The IHS provides healthcare to 2.8 million American Indians and Alaska Natives across the United States through over 687 facilities, including hospitals, health centers, health stations, and school health centers. Approximately 19.3% of individuals utilizing IHS facilities experience chronic pain, with prevalence rates notably higher among women and older adults. &nbsp;</li>
</ul>
</li>
</ul>

MLSS

Milestone Scientific Secures Federal Supply Schedule Approval On Contract For CompuFlo Epidural System

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024
INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Completes  Method Comparison Study On Its Intelligent Fingerprinting Drug Screening System

STK Steakhouse brings its unrivaled VIBE dining experience to Canada, overlooking Niagara Falls
This location is the 30th STK Steakhouse in operation; the new, licensed location is part of the Company's asset light growth strategy
The ONE Group Hospitality, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) today announced the recent opening of the newest <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstksteakhouse.com%2F&amp;esheet=54158249&amp;newsitemid=20241126821548&amp;lan=en-US&amp;anchor=STK+Steakhouse&amp;index=1&amp;md5=88a8fc4bbddacd592e33537cb14b7a88">STK Steakhouse</a> with beautiful views of Niagara Falls, on the Canadian side. Located at 6700 Fallsview Blvd., the new restaurant offers VIBE dining at its finest with incredible views and is situated within the Embassy Suites Hotel. The location offers elevated culinary curations, world-famous cocktails and live music spun by renowned DJs. The opening of STK Niagara Falls offers a new location for locals and tourists alike for sought-after views and an upscale dining experience.

STKS

The ONE Group Hospitality, Inc. Opens New STK Niagara Falls Location;  Location Is The 30th STK Steakhouse In Operation; The New, Licensed Location Is Part Of The Co's Asset Light Growth Strategy

On Tuesday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185604/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52" rel="noreferrer noopener">in obese patients</a>.
The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.
Amgen&#8217;s stock dropped as the results seemed to fall short of Wall Street&#8217;s high expectations. CNBC noted that analysts had hoped MariTide would achieve at least 20% weight loss in the Phase 2 trial, with some <a target="_blank" href="https://www.cnbc.com/2024/11/26/amgen-says-weight-loss-drug-maritide-caused-up-to-20percent-weight-loss-after-a-year.html" rel="noreferrer noopener">aiming</a> for as much as 25%.
The study also showed that a subset of patients who typically lose less weight on GLP-1 therapies achieved up to ~17% average weight loss without a weight loss plateau, lowering their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52.
MariTide also demonstrated improvements in cardiometabolic parameters, including blood pressure, triglycerides, and high-sensitivity C-reactive protein (hs-CRP) across doses. There were no significant increases in free fatty acids.
There was no association between the administration of MariTide and bone mineral density changes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The most common side effects were gastrointestinal, including vomiting, nausea, and constipation. Amgen said the discontinuation rate in the dose escalation arms due to any AE was ~11% and less than 8% for GI-related events. No additional safety signals were identified.
In a separate ongoing Phase 1 pharmacokinetic study, additional dosing regimens have been evaluated in a planned preliminary analysis.
The ongoing Part 2 of the Phase 2 study is investigating MariTide beyond 52 weeks to evaluate further weight loss with continued treatment, weight maintenance through less frequent or lower dosing and durability of weight loss after discontinuation of MariTide.
MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent single-injection administration.
Amgen is also advancing its obesity pipeline, including oral and injectable approaches composed of incretin and non-incretin mechanisms.
Price Action: AMGN stock is down 11.6% at $259.88 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast" target="_blank" rel="noreferrer noopener">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Health Care

Movers

Trading Ideas

AMGN

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

Cadrenal Therapeutics, Inc. (CVKD) has issued an update. Cadrenal Therapeutics has announced a partnership with Abbott to propel its key trial for ...

Cadrenal Therapeutics Partners with Abbott on Cardiac Trial

Abbott to collaborate with Cadrenal on anticoagulant tecarfarin

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cadrenal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvkd-stock-quote/">CVKD</a>) just reported results for the second quarter of 2024.<ul><li>Cadrenal Therapeutics reported earnings per share of -15 cents. This was below the analyst estimate for EPS of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cvkd-stock-earnings-cadrenal-therapeutics-for-q2-of-2024/">CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q2 2024

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. Cadrenal Therapeutics, Inc. has refreshed its investor presentation with detail...

Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully...

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin

Cadrenal Therapeutics (CVKD) has raised gross proceeds of approximately $5.1M through its at-the-market facility, selling an aggregate of 391,243 s...

Cadrenal Therapeutics raises $5.1M via at-the-market facility

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has released its Q3 earnings. Here is a breakdown of the information Cadrenal Therapeutics, Inc. presented ...

Cadrenal Therapeutics Advances Tecarfarin Development

Cadrenal Therapeutics reports Q3 results

16:09 EST Cadrenal Therapeutics (CVKD) files to sell 590K shares of common stock for holders Published first on TheFly – the ultimate source for re...

Comments

Cadrenal Therapeutics

Vendite allo scoperto

Cadrenal Therapeutics (NASDAQ:CVKD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO